CORT 108297

Drug Profile

CORT 108297

Alternative Names: ADS-108297; CORT-108297

Latest Information Update: 13 Nov 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argenta Discovery; Corcept Therapeutics
  • Developer Corcept Therapeutics
  • Class 3-ring heterocyclic compounds; Obesity therapies; Pyrazoles; Quinolines; Small molecules; Sulfones
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psychiatric disorders; Weight gain

Most Recent Events

  • 30 Sep 2014 Discontinued - Phase-I for Psychiatric disorders (In volunteers) in USA (PO)
  • 30 Sep 2014 Discontinued - Phase-I/II for Weight gain in USA (PO)
  • 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top